Alvotech (ALVO)
| Market Cap | 1.03B -69.8% |
| Revenue (ttm) | 588.90M +19.7% |
| Net Income | 27.92M |
| EPS | 0.10 |
| Shares Out | 313.02M |
| PE Ratio | 32.90 |
| Forward PE | 522.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 722,571 |
| Open | 3.130 |
| Previous Close | 3.110 |
| Day's Range | 3.100 - 3.345 |
| 52-Week Range | 3.030 - 11.850 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 8.00 (+143.16%) |
| Earnings Date | Mar 18, 2026 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 143.16% from the latest price.
News
Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commissio...
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website...
Alvotech (ALVO) Q4 2025 Earnings Call Transcript
Alvotech (ALVO) Q4 2025 Earnings Call Transcript
Alvotech Q4 2025 and Full Year 2025 Financial Results
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar...
Royce Smaller-Companies Growth Fund FY 2025: What Worked
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated s...
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldw...
Alvotech Announces Increase in Number of Own Shares
REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announce...
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today an...
Alvotech: Why FDA Delays Don't Break The Bull Case
Alvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033. It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johns...
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Beyond Meat, Inc. (NASDAQ:BYND) ...
Correction: Transactions of Managers and Closely Associated Persons
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. annou...
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition ...
Alvotech Secures Term Loan Facility of USD 100 Million
REYKJAVIK, ICELAND (December 31, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today a...
Changes in company's own shares
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares Notification 29 Dec 2025
Alvotech's Financial Calendar for 2026
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor cal...
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients world...
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
SAN FRANCISCO , Dec. 17, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures re...
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH A...
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
REYKJAVIK, ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announ...
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Alvotech (ALVO) Q3 2025 Earnings Call Transcript
Alvotech ( ALVO) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Benedikt Stefansson - VP of Investor Relations and Global Communications Robert Wessman - CEO, Founder & Exec...
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, November 12, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Alvotech (the “Company”) (NASD...